Danaher (DHR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
25 Mar, 2026Executive summary
Annual meeting scheduled for May 5, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by May 4, 2026.
Voting matters and shareholder proposals
Election of eleven directors to serve until the 2027 annual meeting.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote to approve named executive officer compensation (say-on-pay).
Approval of the Amended and Restated Omnibus Incentive Plan.
Provision to address any other business that may arise at the meeting.
Board of directors and corporate governance
Eleven nominees listed for election, including Rainer M. Blair, Feroz Dewan, Linda Filler, and others.
Board recommends voting in favor of all director nominees.
Latest events from Danaher
- All board nominees, auditor appointment, and executive pay were approved by large majorities.DHR
AGM 20259 Jul 2026 - Strong Q4 results, robust recurring revenue, and high single-digit growth outlook driven by innovation.DHR
43rd Annual J.P. Morgan Healthcare Conference 20258 Jul 2026 - All proposals passed with strong support amid robust financial performance and strategic focus.DHR
AGM 202614 May 2026 - Strong growth in bioprocessing and diagnostics supports a positive full-year outlook.DHR
Bank of America Global Healthcare Conference 202613 May 2026 - Bioprocessing and diagnostics drive growth outlook, with Masimo acquisition boosting long-term returns.DHR
TD Cowen 46th Annual Health Care Conference29 Apr 2026 - Q1 2026 revenue up 3.5% to $6.0B, adjusted EPS up 9.5%, Masimo acquisition announced.DHR
Q1 202621 Apr 2026 - Strong 2025 results, robust recurring revenue, and innovation drive long-term growth outlook.DHR
Corporate presentation21 Apr 2026 - 2026 proxy covers director elections, pay, auditor, incentive plan, and major acquisition.DHR
Proxy filing25 Mar 2026 - 2025 ended with strong growth and cash flow; 2026 guidance targets higher revenue and EPS.DHR
Q4 20253 Feb 2026